Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

Its approval succeeds both the FDA’s accelerated and traditional approvals of Eisai and Biogen’s lecanemab (also known as Leqembi), a similar treatment, in early and mid-2023 respectively.

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...

May 8, 2025 — The drugs, called NRTIs, have the potential to prevent a million cases of Alzheimer's every year, the researchers ... May 7, 2025 — Obstructive sleep apnea, a condition that ...

Consider Spice Testing in Vulvar Dermatitis Complaints Spices and herbs were the second most common allergens identified with patch testing and were clinically relevant.

May 12, 2025 — In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab ...

From our spring 2018 issue of Care and Cure magazine, learn more about the pharmaceutical company Pfizer pulling out of neuroscience research. In January, news hit the headlines that pharmaceutical ...

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

Physicians Weigh in on Coffee Enema Trends Medical pros revisit the 150-year history of coffee enemas to weigh their potential benefits and hidden dangers.